<DOC>
	<DOCNO>NCT00544817</DOCNO>
	<brief_summary>The mechanism action sorafenib make interesting drug investigate treatment patient glioblastoma multiforme . Efficacy agent anti-angiogenic activity already demonstrate PDGF receptor target may also pertinent glioblastoma . The combination temozolomide plus sorafenib investigated previously treatment patient advance melanoma . The combination generally well tolerate ; previously untreated patient , standard dose sorafenib ( 400mg PO bid ) administer temozolomide 150mg/m2 PO daily 5 day , repeat every 28 day ( 23 ) . In multicenter phase II study , patient newly diagnose glioblastoma receive standard treatment , include initial debulking surgical resection ( feasible ) follow high-dose radiation therapy concurrent temozolomide . After completion radiation therapy , patient continue treatment temozolomide ( 150mg/m2 day 1-5 ) sorafenib ( 400mg PO bid daily ) , repeat 28-day interval 6 cycle .</brief_summary>
	<brief_title>Radiation Therapy Temozolomide Followed Temozolomide Plus Sorafenib Glioblastoma Multiforme</brief_title>
	<detailed_description>All patient enter study initially undergo combined modality treatment concurrent radiation therapy + temozolomide . Four week complete radiation therapy , patient begin 6 month follow-up treatment oral temozolomide plus sorafenib . Combined Modality Therapy - Radiation Therapy Radiotherapy must begin within ≤ 6 week surgery . One treatment 2.0Gy give daily 5 day per week total 60.0Gy 6 week . Temozolomide 75mg/m2 PO give daily , begin first day radiation therapy continue last day radiation therapy . After completion combine modality therapy , patient 4 week without therapy . Systemic Therapy Beginning 4 week completion radiation therapy , patient receive 6 month treatment temozolomide sorafenib . Temozolomide 150mg/m2 orally administer day 1-5 , repeat every 28 day 6 course . Sorafenib 400mg PO bid administer day 1-28 , repeat 6 course concurrently temozolomide</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically confirm intracranial glioblastoma multiforme ( WHO grade 4 ) . 2 . Patients partial complete surgical debulking eligible , inoperable glioblastoma . 3 . No previous treatment glioblastoma except previous surgical debulking ( i.e . previous radiotherapy , local chemotherapy , systemic therapy ) . 4 . ECOG performance status 0 1 ( See Appendix C ) 5 . Age ≥ 18 year 6 . Adequate bone marrow function : hemoglobin ≥ 9.0g/dL ; ANC ≥ 1500/μL ; platelet count ≥ 100,000/μL . 7 . Adequate liver function Total bilirubin ≤ 1.5 x ULN ALT AST ≤ 2.5 x ULN 8 . Serum creatinine &lt; 1.5 x ULN 9 . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Women must agree breast feed receive study treatment . 10 . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) receive study treatment . Women use adequate birth control least 3 month last administration sorafenib . 11 . INR &lt; 1.5 PT/PTT within normal limit patient receive anticoagulation . However , patient receive anticoagulation treatment agent warfarin heparin also eligible . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . 12 . Patients must ability understand willingness sign write informed consent . A sign informed consent must obtain prior studyspecific procedure . 1 . Patients must ability swallow whole pill . 2 . Active cardiac disease : congestive heart failure &gt; class 2 NYHA ( Appendix D ) ; unstable angina new onset angina within last 3 month ; myocardial infarction within last 6 month . 3 . Cardiac ventricular arrhythmia require antiarrhythmic therapy 4 . Uncontrolled hypertension define systolic blood pressure &gt; 150mm Hg diastolic pressure &gt; 90mm Hg , despite optimal medical management 5 . Known human immunodeficiency virus ( HIV ) infection chronic hepatitis B C infection 6 . Active clinically serious infection &gt; grade 2 7 . Thrombotic embolic event include cerebral vascular accident TIAs within past 6 month 8 . Pulmonary hemorrhage/bleeding event ≥ grade 2 within 4 week first dose sorafenib 9 . Any hemorrhage/bleeding event ≥ grade 3 within 4 week first dose sorafenib 10 . Serious nonhealing wound , ulcer , bone fracture 11 . Evidence history bleed diathesis coagulopathy 12 . Major surgery , open biopsy , significant traumatic injury within 4 week begin treatment sorafenib 13 . Use St. John 's Wort rifampicin 14 . Known suspected allergy sorafenib temozolomide 15 . Any malabsorption problem 16 . Other active malignancy , treatment invasive cancer within last 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Concurrent Radiation Therapy</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>First-line</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Phase II</keyword>
</DOC>